DR. GREGORY MARK GLENN, MD
Medical Practice at Montevideo Rd, Poolesville, MD

2006000, Jan 5, 2006

Apr 20, 2005

11/109948

Gregory Glenn - Poolesville MD, US
Carl Alving - Bethesda MD, US

A61K 39/145

424209100

Transcutaneous immunization can deliver antigen to the immune system through the stratum corneum without physical or chemical penetration to the dermis layer of the skin. This delivery system induces an antigen-specific immune response. Use of skin-active adjuvants is preferred. Although perforation of intact skin is not required, superficial penetration or micropenetration of the skin can act as an enhancer; similarly, hydration may enhance the immune response. This system can induce antigen-specific immune effectors after epicutaneous application of a formulation containing one or more antigen and adjuvant. The formulation may initiate processes such as antigen uptake, processing, and presentation; Langerhans cell activation, migration from the skin to other immune organs, and differentiation to mature dendritic cells; contacting antigen with lymphocytes bearing cognate antigen receptors on the cell surface and their stimulation; and combinations thereof. Systemic and/or regional immunity may be induced; immune responses that result in prophylaxis and/or therapeutic treatments are preferred. Antigen and adjuvant activities in the formulation may be found in the same molecule, two or more different molecules dissociated from each other, or multiple molecules in a complex formed by covalent or non-covalent bonds. For antigens and adjuvants which are proteinaceous, they may be provided in the formulation as a polynucleotide for transcutaneous genetic immunization. Besides simple application of a liquid formulation, patches or other medical devices may be used to deliver antigen for immunization.

2007008, Apr 19, 2007

Sep 5, 2006

11/516462

Gregory Glenn - Poolesville MD, US
Kyle Doerksen - Los Altos Hills CA, US
Larry Ellingsworth - Rockville MD, US
Diane Epperson - Bethesda MD, US
David Frerichs - Poolesville MD, US
Mervyn Hamer - Gaithersburg MD, US
Aaron Henningsgaard - Palo Alto CA, US
Matthew Inouye - Foster City CA, US
Adrian James - Palo Alto CA, US
Jonathan Kaplan - Palo Alto CA, US
John Lai - San Bruno CA, US
Robert Lister - Dronfield, GB
David Lubensky - San Francisco CA, US
Peter MacDonald - Palo Alto CA, US
Sally Madsen - San Francisco CA, US
Brian Mason - Simsbury CT, US
Christine McElhaney - Palo Alto CA, US
Lionel Mohri - Santa Clara CA, US
Anthony Pigliacampo - Menlo Park CA, US
Gina Romero - Soquel CA, US
Charles Steeves - Pte. Du Chene, CA
Christina Villar - North Potomac MD, US
Jianmei Yu - Bethesda MD, US

Iomai Corporation - Gaithersburg MD

A61B 17/20

604046000

The invention provides devices for the disruption of one or more layers of skin and methods of their use to administer therapeutic agents, e.g., antigens or drugs. The devices are designed to disrupt a defined area of skin. The defined area can approximate the area that a patch or other suitable vehicle for therapeutic agent, e.g., drug or vaccine, delivery is designed to contact. Exemplary devices employ a mask to define the area to be disrupted. Other devices disrupt a defined area by rotating in place. For devices that employ a mask that is secured to the skin, the invention provides methods of disrupting the stratum corneum by first securing the mask to the skin and then disrupting the skin. For rotating devices, the disrupting member is simply placed against the skin and actuated to effect disruption.

2011024, Oct 6, 2011

Jan 21, 2011

13/011071

Gregory M. Glenn - Poolesville MD, US
Carl R. Alving - Bethesda MD, US

A61K 39/00, A61K 39/12, A61K 39/02, A61K 39/108, A61K 39/07, A61P 37/04, A61P 31/12, A61P 31/16, A61P 31/14, A61P 31/10, A61P 33/00, A61P 31/04, A61M 5/00, A61M 37/00, A61N 1/30

4241921, 4241841, 4241931, 4242041, 4242341, 4242651, 4242741, 4242091, 4242241, 4242571, 4242461, 604173, 604131, 604 1, 604 22, 604 20

Transcutaneous immunization can deliver antigen to the immune system through the stratum corneum without physical or chemical penetration to the dermis layer of the skin. This delivery system induces an antigen-specific immune response. Use of skin-active adjuvants is preferred. Although perforation of intact skin is not required, superficial penetration or micropenetration of the skin can act as an enhancer; similarly, hydration may enhance the immune response. This system can induce antigen-specific immune effectors after epicutaneous application of a formulation containing one or more antigen and adjuvant. The formulation may initiate processes such as antigen uptake, processing, and presentation; Langerhans cell activation, migration from the skin to other immune organs, and differentiation to mature dendritic cells; contacting antigen with lymphocytes bearing cognate antigen receptors on the cell surface and their stimulation; and combinations thereof. Systemic and/or regional immunity may be induced; immune responses that result in prophylaxis and/or therapeutic treatments are preferred. Antigen and adjuvant activities in the formulation may be found in the same molecule, two or more different molecules dissociated from each other, or multiple molecules in a complex formed by covalent or non-covalent bonds. For antigens and adjuvants which are proteinaceous, they may be provided in the formulation as a polynucleotide for transcutaneous genetic immunization. Besides simple application of a liquid formulation, patches or other medical devices may be used to deliver antigen for immunization.

2004013, Jul 15, 2004

Mar 12, 2004

10/472598

Gregory Glenn - Poolesville MD, US
Jianmei Yu - Bethesda MD, US
Mervyn Hamer - Gaithersburg MD, US
Jesus Miranda - Miami FL, US
Christopher Adams - Miramar FL, US

A61K039/00, A61K039/38

424/184100

A protein-in-adhesive patch for transcutaneous immunization is described with at least four different components: (i) backing layer; (ii) pressure-sensitive adhesive adhering to the backing layer; (iii) at last one immunologically-active protein of an immunogenic formulation applied to the pressure-sensitive adhesive layer opposite the backing layer and/or incorporated in the pressure-sensitive adhesive layer such that the at least one protein is in contact with adhesive; and (iv) stabilizer which maintains the immunological activity of the at least one protein under ambient conditions.

2004010, Jun 10, 2004

May 12, 2003

10/435676

Gregory Glenn - Poolesville MD, US
Larry Ellingsworth - Rockville MD, US
Scott Hammond - Olney MD, US

IOMAI CORPORATION

A61K039/00

424/185100

Transcutaneous immunostimulation administers at least one adjuvant by transcutaneous immunization to a subject who has undergone, is undergoing, or will undergo conventional vaccination or another immune response. A subject is selected for treatment to stimulate the immune response to a conventional vaccine or other immunotherapy. A suspicion, medical history, or determination by a physician or veterinarian that the subject may fail to respond or only poorly respond to conventional vaccination or other immunotherapy because of age, acquired or congenital immunodeficiency, immunosuppression caused by disease or ablative therapy, or the use of reduced amounts of antigen in the conventional vaccine can be used to select subjects in need of treatment.

2004018, Sep 23, 2004

May 13, 2004

10/472393

Gregory Glenn - Poolesville MD, US
Howard Six - Lewisburg TN, US

A61K039/00

424/184100

Transcutaneous immunostimulation administers at least one adjuvant by transcutaneous immunization to a subject who has undergone, is undergoing, or will undergo conventional vaccination. A subject is selected for treatment to stimulate the immune response to a conventional vaccine. A suspicion, medical history, or determination by a physician or veterinarian that the subject may fail to respond or only poorly respond to conventional vaccination because of age, acquired or congenital immunodeficiency, immunosuppression caused by disease or ablative therapy, or the use of reduced amounts of antigen in the conventional vaccine can be used to select subjects in need of treatment

7527802, May 5, 2009

Feb 13, 2002

10/467887

Gregory M. Glenn - Poolesville MD, US
Frederick J. Cassels - Laurel MD, US

The United States of America as represented by the Secretary of the Army - Washington DC

A61K 39/38, A61K 39/02, A61K 39/385, A61K 39/108, A61K 38/00, A61K 9/70, A61K 9/127, A61F 13/00, A01N 37/18, A01N 63/00, A01N 65/00, A61B 17/20, A61M 37/00

4242571, 4241841, 4242421, 4242341, 4241901, 424 931, 4242411, 4242351, 4241941, 424449, 424450, 514 2, 514 12, 604 46

A vaccine delivered by transcutaneous immunization provides an effective treatment against infections by pathogens such as, for example, enterotoxigenic (ETEC) and/or for symptoms of diarrheal disease caused thereby. For example, one, two, three, four, five or more antigens derived from ETEC and capable of inducing an antigen-specific immune response (e. g. , toxins, colonization or virulence factors) and one or more optional adjuvant (e. g. , whole bacterial ADP-ribosylating exotoxins, B subunits or toxoids thereof, detoxified mutants and derivatives thereof) are used to manufacture vaccines or to induce systemic and/or mucosal immunity.

2009013, May 28, 2009

Aug 6, 2007

11/882888

Gregory M. Glenn - Poolesville MD, US
Larry R. Ellingsworth - Rockville MD, US
Scott A. Hammond - Olney MD, US

Iomai Corporation - Gaithersburg MD

A61K 39/395, A61K 39/00

4241301, 4241841

Transcutaneous immunostimulation administers at least one adjuvant by transcutaneous immunization to a subject who has undergone, is undergoing, or will undergo conventional vaccination or another immune response. A subject is selected for treatment to stimulate the immune response to a conventional vaccine or other immuno-therapy. A suspicion, medical history, or determination by a physician or veterinarian that the subject may fail to respond or only poorly respond to conventional vaccination or other immunotherapy because of age, acquired or congenital immunodeficiency, immunosuppression caused by disease or ablative therapy, or the use of reduced amounts of antigen in the conventional vaccine can be used to select subjects in need of treatment.